- Home
- PRPO vs STAI Comparison
PRPO vs STAI Comparison
Compare PRPO & STAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- STAI
- Stock Information
- Founded
- PRPO N/A
- STAI 2011
- Country
- PRPO United States
- STAI United States
- Employees
- PRPO N/A
- STAI N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- STAI
- Sector
- PRPO Industrials
- STAI
- Exchange
- PRPO Nasdaq
- STAI Nasdaq
- Market Cap
- PRPO 22.0M
- STAI 24.6M
- IPO Year
- PRPO N/A
- STAI N/A
- Fundamental
- Price
- PRPO $17.59
- STAI $0.48
- Analyst Decision
- PRPO
- STAI
- Analyst Count
- PRPO 0
- STAI 0
- Target Price
- PRPO N/A
- STAI N/A
- AVG Volume (30 Days)
- PRPO 16.8K
- STAI 5.0M
- Earning Date
- PRPO 11-05-2025
- STAI 10-26-2025
- Dividend Yield
- PRPO N/A
- STAI N/A
- EPS Growth
- PRPO N/A
- STAI N/A
- EPS
- PRPO N/A
- STAI N/A
- Revenue
- PRPO $21,242,000.00
- STAI $907,637.00
- Revenue This Year
- PRPO N/A
- STAI N/A
- Revenue Next Year
- PRPO N/A
- STAI N/A
- P/E Ratio
- PRPO N/A
- STAI N/A
- Revenue Growth
- PRPO 27.05
- STAI N/A
- 52 Week Low
- PRPO $3.90
- STAI $0.35
- 52 Week High
- PRPO $22.38
- STAI $9.07
- Technical
- Relative Strength Index (RSI)
- PRPO 54.11
- STAI 51.90
- Support Level
- PRPO $17.00
- STAI $0.35
- Resistance Level
- PRPO $22.38
- STAI $0.50
- Average True Range (ATR)
- PRPO 1.35
- STAI 0.04
- MACD
- PRPO -0.13
- STAI 0.02
- Stochastic Oscillator
- PRPO 40.83
- STAI 84.97
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
About STAI ScanTech AI Systems Inc. Common stock
ScanTech AI Systems Inc is developing and deploying security screening systems that protect travelers and other public members from criminals, terrorists, and other bad actors. It has developed a proprietary Computed Tomography scanning system that uses fixed-gantry technology to detect explosives, weapons, narcotics, and other contraband.